Figure 1

Molecular-guided therapy prediction process. A) Each MPNST sample is compared to a benign tumor tissue reference pool and processed as shown. Consolidated reports include individual rankings of therapeutics for each sample (see Table 1 and Additional file 2). B) Summary graph depicting microarray signal intensity for transcripts contributing to molecular-guided therapy predictions in MPNST samples in comparison with benign neurofibromas. Additional graphs for increased visibility of individual results are also provided in Additional file 4.